Despite being the activator of RAS signalling pathway, EGFR derives less attention in this aspect due to activating mutations in KRAS, which are significantly associated with lack of response or resistance with some of the EGFR inhibitors like cetuximab in colorectal and lung cancers [58,60]. The gene discussed is KRAS; the disease is lung cancer.